NCT04143711 2026-03-18
Study of DF1001 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Phase 1/2 Completed
Dragonfly Therapeutics
Shanghai Yizhong Pharmaceutical Co., Ltd.
Actuate Therapeutics Inc.
Eli Lilly and Company
Prescient Therapeutics, Ltd.
EpiAxis Therapeutics